LENZ THERAPEUTICS, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-82.1M | $-49.8M | $-70.0M | $-101.1M | $-70.8M | $-68.4M |
| Depreciation & Amortization | $287.0K | $58.0K | $15.0K | $2.4M | $734.0K | $121.0K |
| Depreciation | — | — | $2.4M | $2.4M | $700.0K | $100.0K |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $12.5M | $6.4M | $1.3M | $13.5M | $7.9M | $177.0K |
| Net Cash from Operating Activities | $-69.2M | $-59.4M | $-60.4M | $-88.0M | $-52.9M | $-8.7M |
| Investing Activities | ||||||
| Capital Expenditures | $827.0K | $468.0K | $30.0K | $6.6M | $5.7M | $1.5M |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-75.7M | $-154.5M | $-29.6M | $-241.9M | $-5.7M | $-1.5M |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $149.7M | $199.0M | $80.7M | $597.0K | $417.5M | $30.1M |
| Net Change in Cash | $4.9M | $-14.9M | $-9.3M | $-329.2M | $358.9M | $19.8M |
| Free Cash Flow | $-70.0M | $-59.9M | $-60.4M | $-94.6M | $-58.6M | $-10.3M |